Lipusu |
Liposomal formulation of paclitaxel |
Not available |
Metastatic breast cancer (Phase IV, NCT02142790), advanced solid tumors (Phase IV, NCT01994031). |
MCC-465 |
Targeted liposomal formulation of doxorubicin |
143 |
Metastatic stomach cancer (Phase I/II in Japan). |
SGT-53 |
Targeted liposomal formulation of p53 gene |
115 |
Solid tumors (Phase I, NCT00470613), metastatic pancreatic cancer (Phase II, NCT02340117), refractory or recurrent solid tumors (Phase I, NCT02354547), recurrent glioblastoma (Phase II, NCT02354547). |
PICN |
Paclitaxel injection concentrate for nanodispersion |
100 |
Metastatic or recurrent breast cancer (phase I, NCT02136927), solid tumors in advanced stages (Phase I, NCT01305512, NCT01304303). |
MM-398 |
Liposomal formulation of irinotecan |
100 |
Gastric or gastro-esophageal junction adenocarcinoma (Phase II 44), pediatric solid tumors (Phase I, NCT02013336), various breast cancers (Phase I, NCT01770353), high grade gliomas (Phase I, NCT02022644). |
TIL |
Liposomal formulation of topotecan |
100 |
Small cell lung cancer, ovarian cancer, other advanced tumors (Phase I, NCT00765973). |
VIL |
Liposomal formulation of vinorelbine |
100 |
Advanced solid tumors (Phase I, NCT00364676). |
Thermodox |
Heat-activated liposomal formulation of doxorubicin |
100 |
Liver cancer (Phase III, NCT00617981, NCT02112656, Phase I, NCT02181075), breast cancer (Phase I/II, NCT00826085). |
LiPlaCis |
Liposomal formulation of cisplatin |
Not available |
Advanced or refractory solid tumors (Phase I, NCT01861496). |
BIND-014 |
Targeted polymeric nanoparticle containing docetaxel |
100 |
Prostate cancer (Phase II, NCT01812746, 41) and non-small cell lung cancer (Phase II, NCT01792479). |
NK105 |
Micellar polymeric nanoparticle incorporating paclitaxel |
85 |
Metastatic or recurrent breast cancer (Phase III, NCT01644890). |
TKM- 080301 |
Liposomal formulation of PLK1 siRNA |
80 |
Neuroendocrine tumors, Adrenocortical carcinoma (Phase I/II, NCT01262235). |
Atu027 |
Liposomal formulation of PKN3 siRNA |
Not Available |
Advanced or metastatic pancreatic cancer (Phase I/II, NCT01808638). |
CALAA-01 |
Targeted polymeric nanoparticle containing gene silencing RNA |
75 |
Various cancers (Phase I 45). |
NC-6300 |
Micellar polymeric nanoparticle incorporating epirubicin |
40–80 |
Various cancers (Phase I, in Japan) |
NC-4016 |
Micellar polymeric nanoparticle incorporating oxaliplatin |
40 |
Advanced solid tumors or lymphomas (Phase I, NCT01999491). |
CRLX101 |
Cyclodextrin-containing polymer conjugated to camptothecin |
30–40 |
Recurrent non-small cell lung cancer (Phase II, NCT01803269), metastatic renal cell carcinoma (Phase II, NCT02187302), ovarian/tubal/peritoneal cancer (Phase II, NCT01652079, Phase I, NCT02389985), rectal cancer (Phase I/II, NCT02010567). |
Genexol-PM |
Micellar polymeric nanoparticle incorporating paclitaxel |
20–50 |
Metastatic breast cancer (Phase II, NCT01784120), head and neck cancer (Phase II, NCT01689194). |
NC-6004 |
Micellar polymeric nanoparticle incorporating cispatlin |
20 |
Locally advanced or metastatic pancreatic cancer (Phase III, NCT02043288) and non-small cell lung cancer (Phase I/II, NCT02240238). |